Supernus Pharmaceuticals Inc (SUPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
44
About the Report
About the Report
Summary
Supernus Pharmaceuticals Inc (Supernus) is a specialty pharmaceutical company which develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company's neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; and Trokendi XR (topiramate), an initial monotherapy against partial onset or primary generalized tonic-clonic seizures and an adjunct therapy for the treatment of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome. Its technology platforms include Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The company operates through its subsidiary Supernus Europe Ltd. Supernus is headquartered in Rockville, Maryland, the US.
Supernus Pharmaceuticals Inc (SUPN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Supernus Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
HealthCare Royalty Acquires Orenitram from Supernus Pharma for USD30 Million 10
Licensing Agreements 11
Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 11
Aequus Pharma Enters into Licensing Agreement with Supernus Pharma 12
Especificos Stendhal Enters into Licenisng Agreement with Supernus Pharma 13
Equity Offering 14
Supernus Pharma Completes Public Offering Of Common Stock For USD 48 Million 14
Supernus Pharma Completes IPO For USD52.3 Million 16
Debt Offering 18
Supernus Pharma Raises USD402.5 Million in Private Placement of Notes Due 2023 18
Supernus Pharma Completes Private Placement Of Notes Due 2019 For USD 90 Million 19
Acquisition 21
Supernus Pharma to Acquire Biscayne Neurotherapeutics 21
Supernus Pharmaceuticals Inc-Key Competitors 23
Supernus Pharmaceuticals Inc-Key Employees 24
Supernus Pharmaceuticals Inc-Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 06, 2018: Supernus announces third quarter 2018 financial results and record quarterly revenue 26
Aug 07, 2018: Supernus announces second quarter 2018 financial results and record quarterly revenue 28
May 08, 2018: Supernus Reports First Quarter 2018 Financial Results 30
Feb 27, 2018: Supernus Announces Record Full Year 2017 Financial Results, Exceeding Operating Earnings Guidance 32
Nov 06, 2017: Supernus Announces Third Quarter 2017 Financial Results 34
Aug 02, 2017: Supernus Announces Record Second Quarter 2017 Financial Results 36
May 09, 2017: Supernus Announces First Quarter 2017 Financial Results 38
Feb 28, 2017: Supernus Announces Record Fourth Quarter and Full Year 2016 Financial Results 40
Corporate Communications 42
Jun 27, 2018: Supernus Pharmaceuticals Names Dr. Carrolee Barlow As Board Director 42
Clinical Trials 43
Sep 18, 2017: Supernus Provides Update on SPN-810 Phase III Clinical Trials 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44
List of Figure
List of Figures
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List of Table
List of Tables
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Supernus Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
HealthCare Royalty Acquires Orenitram from Supernus Pharma for USD30 Million 10
Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 11
Aequus Pharma Enters into Licensing Agreement with Supernus Pharma 12
Especificos Stendhal Enters into Licenisng Agreement with Supernus Pharma 13
Supernus Pharma Completes Public Offering Of Common Stock For USD 48 Million 14
Supernus Pharma Completes IPO For USD52.3 Million 16
Supernus Pharma Raises USD402.5 Million in Private Placement of Notes Due 2023 18
Supernus Pharma Completes Private Placement Of Notes Due 2019 For USD 90 Million 19
Supernus Pharma to Acquire Biscayne Neurotherapeutics 21
Supernus Pharmaceuticals Inc, Key Competitors 23
Supernus Pharmaceuticals Inc, Key Employees 24
Supernus Pharmaceuticals Inc, Subsidiaries 25
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.